Denali Therapeutics Other Current Liabilities

Denali Therapeutics (DNLI) currently reports a other current liabilities of $78M as of June 2026. That compares with $71M in the prior-year period — up 9.7% year over year. Use the charts on this page to explore Denali Therapeutics's other current liabilities history and peer comparisons.

Denali Therapeutics's other current liabilities increased from $71M to $78M — a 9.7% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Denali Therapeutics reported $78M in other current liabilities as of June 2026. That compares with $71M in the prior-year period — up 9.7% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current other current liabilities of $78M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Denali Therapeutics, and consider following DNLI for alerts when major investors trade the stock.

Denali Therapeutics is classified in the Healthcare sector. On other current liabilities, it currently shows $78M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing DNLI with unrelated industries.